Proton pump inhibitor use significantly increases the risk of spontaneous bacterial peritonitis in 1965 patients with cirrhosis and ascites: a propensity score matched cohort study

The risk of spontaneous bacterial peritonitis (SBP) associated with proton pump inhibitor (PPI) use has been raised in cirrhotic patients with ascites. However, this is based on case–control studies, often with a small series.

[1]  P. Erwin,et al.  Association between Proton Pump Inhibitor Therapy and Clostridium difficile Infection: A Contemporary Systematic Review and Meta-Analysis , 2012, PloS one.

[2]  P. Siersema,et al.  Proton pump inhibitor therapy predisposes to community‐acquired Streptococcus pneumoniae pneumonia , 2012, Alimentary pharmacology & therapeutics.

[3]  Mark A. Miller,et al.  Editorial: How Much Do PPIs Contribute to C. difficile Infections? , 2012, The American Journal of Gastroenterology.

[4]  D. van Duin,et al.  Increased rate of spontaneous bacterial peritonitis among cirrhotic patients receiving pharmacologic acid suppression. , 2012, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[5]  A. Gerbes,et al.  Spontaneous bacterial peritonitis: recent guidelines and beyond , 2011, Gut.

[6]  Myung-Gyu Choi,et al.  Practice Pattern of Gastroenterologists for the Management of GERD Under the Minimal Influence of the Insurance Reimbursement Guideline: A Multicenter Prospective Observational Study , 2011, Journal of Korean medical science.

[7]  D. Bauer,et al.  Proton pump inhibitors and risk of fractures: a meta-analysis of 11 international studies. , 2011, The American journal of medicine.

[8]  G. Trikudanathan,et al.  Association between proton pump inhibitors and spontaneous bacterial peritonitis in cirrhotic patients – a systematic review and meta‐analysis , 2011, International journal of clinical practice.

[9]  Kyeong Ok Kim,et al.  Association between acid suppressive therapy and spontaneous bacterial peritonitis in cirrhotic patients with ascites , 2011, Scandinavian journal of gastroenterology.

[10]  Amy Linsky,et al.  Proton pump inhibitors and risk for recurrent Clostridium difficile infection. , 2010, Archives of internal medicine.

[11]  M. Loeb,et al.  Meta‐analysis: proton pump inhibitor use and the risk of community‐acquired pneumonia , 2010, Alimentary pharmacology & therapeutics.

[12]  E. Cholongitas,et al.  β‐Blockers protect against spontaneous bacterial peritonitis in cirrhotic patients: a meta‐analysis , 2009, Liver international : official journal of the International Association for the Study of the Liver.

[13]  C. Donskey,et al.  Examination of Potential Mechanisms To Explain the Association between Proton Pump Inhibitors and Clostridium difficile Infection , 2009, Antimicrobial Agents and Chemotherapy.

[14]  W. Chey,et al.  Treatment patterns and symptom control in patients with GERD: US community-based survey , 2009, Current medical research and opinion.

[15]  K. Koh,et al.  Clinical significance and outcome of nosocomial acquisition of spontaneous bacterial peritonitis in patients with liver cirrhosis. , 2009, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[16]  R. Hoffmann,et al.  Association of Proton Pump Inhibitor Therapy With Spontaneous Bacterial Peritonitis in Cirrhotic Patients With Ascites , 2009, The American Journal of Gastroenterology.

[17]  P Michael Ho,et al.  Risk of adverse outcomes associated with concomitant use of clopidogrel and proton pump inhibitors following acute coronary syndrome. , 2009, JAMA.

[18]  S. Hennessy,et al.  Proton-Pump Inhibitor Use and the Risk for Community-Acquired Pneumonia , 2008, Annals of Internal Medicine.

[19]  Jennifer Hill,et al.  Discussion of research using propensity‐score matching: Comments on ‘A critical appraisal of propensity‐score matching in the medical literature between 1996 and 2003’ by Peter Austin, Statistics in Medicine , 2008, Statistics in medicine.

[20]  K. Obstein,et al.  Association between Proton Pump Inhibitor Use and Spontaneous Bacterial Peritonitis , 2008, Digestive Diseases and Sciences.

[21]  K. Obstein,et al.  Association Between Model for End-Stage Liver Disease and Spontaneous Bacterial Peritonitis , 2007, The American Journal of Gastroenterology.

[22]  M. Navasa,et al.  Primary prophylaxis of spontaneous bacterial peritonitis delays hepatorenal syndrome and improves survival in cirrhosis. , 2007, Gastroenterology.

[23]  C. Metge,et al.  The Prevalence of and the Clinical and Demographic Characteristics Associated With High-Intensity Proton Pump Inhibitor Use , 2007, The American Journal of Gastroenterology.

[24]  P. Miner,et al.  Comparison of gastric pH with omeprazole magnesium 20.6 mg (Prilosec OTC) o.m. famotidine 10 mg (Pepcid AC) b.d. and famotidine 20 mg b.d. over 14 days of treatment , 2006, Alimentary pharmacology & therapeutics.

[25]  D. Fone,et al.  Proton pump inhibitor therapy is a risk factor for Clostridium difficile‐associated diarrhoea , 2006, Alimentary pharmacology & therapeutics.

[26]  F. Căruntu,et al.  Spontaneous bacterial peritonitis: pathogenesis, diagnosis, treatment. , 2006, Journal of gastrointestinal and liver diseases : JGLD.

[27]  R. D'Agostino.  Adjustment Methods: Propensity Score Methods for Bias Reduction in the Comparison of a Treatment to a Non‐Randomized Control Group , 2005 .

[28]  R. Wiest,et al.  Bacterial translocation (BT) in cirrhosis , 2005, Hepatology.

[29]  A. Ramachandran,et al.  Intestinal mucosal alterations in experimental cirrhosis in the rat: Role of oxygen free radicals , 2002, Hepatology.

[30]  J. Aponte,et al.  Small intestinal bacterial overgrowth in patients with cirrhosis: prevalence and relation with spontaneous bacterial peritonitis , 2001, American Journal of Gastroenterology.

[31]  E. Cabré,et al.  Effect of cisapride on intestinal bacterial overgrowth and bacterial translocation in cirrhosis , 2000, Hepatology.

[32]  Dekkers,et al.  Comparison of rabeprazole 20 mg versus omeprazole 20 mg in the treatment of active duodenal ulcer: a European multicentre study , 1999, Alimentary pharmacology & therapeutics.

[33]  Chi-Sen Chang,et al.  Small intestine dysmotility and bacterial overgrowth in cirrhotic patients with spontaneous bacterial peritonitis , 1998, Hepatology.

[34]  C. Guarner,et al.  Intestinal bacterial overgrowth and bacterial translocation in cirrhotic rats with ascites. , 1997, Journal of hepatology.

[35]  S. O'keefe,et al.  Altered bowel function and duodenal bacterial overgrowth in patients treated with omeprazole , 1996, Alimentary pharmacology & therapeutics.

[36]  T. Poynard,et al.  Meta-analysis of randomized clinical trials comparing lansoprazole with ranitidine or famotidine in the treatment of acute duodenal ulcer. , 1995, European Journal of Gastroenterology and Hepathology.

[37]  M. Andreu,et al.  Risk factors for spontaneous bacterial peritonitis in cirrhotic patients with ascites. , 1993, Gastroenterology.

[38]  J. Llach,et al.  Incidence and predictive factors of first episode of spontaneous bacterial peritonitis in cirrhosis with ascites: Relevance of ascitic fluid protein concentration , 1992, Hepatology.

[39]  J. Castellote,et al.  Comparison of two ascitic fluid culture methods in cirrhotic patients with spontaneous bacterial peritonitis. , 1990, The American journal of gastroenterology.

[40]  J. Llach,et al.  Norfloxacin prevents spontaneous bacterial peritonitis recurrence in cirrhosis: Results of a double‐blind, placebo‐controlled trial , 1990, Hepatology.

[41]  C. Wells.  Relationship between intestinal microecology and the translocation of intestinal bacteria , 1990, Antonie van Leeuwenhoek.

[42]  F. Epstein,et al.  The physiology of gastric acid secretion. , 1988, The New England journal of medicine.

[43]  M. Vela,et al.  Clinical Practice Guideline For the Diagnosis and Management of Gastroesophageal Reflux Disease , 2013 .

[44]  J. Such,et al.  Spontaneous Bacterial Peritonitis , 1997, Seminars in liver disease.

[45]  J. Bader,et al.  Clinical efficacy of pantoprazole compared with ranitidine , 1994, Alimentary pharmacology & therapeutics.

[46]  J. Delchier,et al.  Clinical efficacy of pantoprazole compared with ranitidine. , 1994 .

[47]  J. Llach,et al.  Recurrence of spontaneous bacterial peritonitis in cirrhosis: Frequency and predictive factors , 1988, Hepatology.